Scarica l'app Stockscreener
5.70
3.45%
0.19
Pre-mercato:
5.73
0.03
+0.53%
Precedente Chiudi:
$5.51
Aprire:
$5.55
Volume 24 ore:
389.93K
Relative Volume:
0.92
Capitalizzazione di mercato:
$85.51M
Reddito:
-
Utile/perdita netta:
$-64.47M
Rapporto P/E:
-0.9216
EPS:
-6.1852
Flusso di cassa netto:
$-52.33M
1 W Prestazione:
-2.90%
1M Prestazione:
-73.57%
6M Prestazione:
-71.84%
1 anno Prestazione:
-48.28%
Intervallo 1D:
$5.52
$5.84
Intervallo di 1 settimana:
$5.25
$6.0271
Portata 52W:
$5.25
$31.01
Jasper Therapeutics Inc Stock (JSPR) Company Profile
Nome
Jasper Therapeutics Inc
Settore
Industria
Telefono
(650) 549-1400
Indirizzo
2200 BRIDGE PKWY SUITE #102, REDWOOD CITY
Confronta JSPR con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
JSPR
Jasper Therapeutics Inc
|
5.70 | 85.51M | 0 | -64.47M | -52.33M | -6.1852 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Jasper Therapeutics Inc Stock (JSPR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-06 | Iniziato | BMO Capital Markets | Outperform |
| 2024-09-09 | Iniziato | JMP Securities | Mkt Outperform |
| 2024-07-08 | Iniziato | BTIG Research | Buy |
| 2024-06-27 | Iniziato | Stifel | Buy |
| 2024-05-06 | Iniziato | H.C. Wainwright | Buy |
| 2024-04-03 | Iniziato | Evercore ISI | Outperform |
| 2024-03-28 | Iniziato | RBC Capital Mkts | Outperform |
| 2024-03-18 | Iniziato | TD Cowen | Outperform |
| 2023-08-11 | Iniziato | CapitalOne | Overweight |
| 2022-02-28 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-11-08 | Iniziato | Credit Suisse | Outperform |
| 2021-10-21 | Iniziato | William Blair | Outperform |
| 2021-10-20 | Iniziato | BMO Capital Markets | Outperform |
| 2021-10-13 | Iniziato | Oppenheimer | Outperform |
Mostra tutto
Jasper Therapeutics Inc Borsa (JSPR) Ultime notizie
Jasper Therapeutics, Inc. (NASDAQ:JSPR) Shares Purchased by Barclays PLC - Defense World
Short Interest in Jasper Therapeutics, Inc. (NASDAQ:JSPR) Rises By 12.1% - Defense World
Short Interest in Jasper Therapeutics, Inc. (NASDAQ:JSPR) Grows By 12.1% - MarketBeat
HC Wainwright Cuts Jasper Therapeutics (NASDAQ:JSPR) Price Target to $40.00 - Defense World
What is HC Wainwright’s Forecast for JSPR Q1 Earnings? - Defense World
What is HC Wainwright's Estimate for JSPR Q1 Earnings? - MarketBeat
Jane Street Group LLC Takes $251,000 Position in Jasper Therapeutics, Inc. (NASDAQ:JSPR) - Defense World
What is HC Wainwright’s Estimate for JSPR FY2029 Earnings? - Defense World
Royal Bank of Canada Lowers Jasper Therapeutics (NASDAQ:JSPR) Price Target to $48.00 - Defense World
Jasper Therapeutics' SWOT analysis: briquilimab's potential in mast cell diseases - Investing.com India
Stock summary: Jasper Therapeutics witnessed loss overall loss of 67.19% throughout the week - Business Upturn
Jasper Therapeutics (NASDAQ:JSPR) Price Target Cut to $40.00 by Analysts at HC Wainwright - MarketBeat
What is HC Wainwright's Forecast for JSPR FY2029 Earnings? - MarketBeat
Amplitude Healthcare Acquisition (OTCMKTS:AMHCU) Announces Positive Preliminary Data from Jasper Therapeutics, Inc. BEACON Phase 1b/2a StudyOn January 8, 2025, Jasper Therapeutics, Inc. released a press release detailing encouraging preliminar - Defense World
Jasper Therapeutics (NASDAQ:JSPR) Price Target Cut to $48.00 by Analysts at Royal Bank of Canada - MarketBeat
BMO maintains Jasper Therapeutics Outperform rating By Investing.com - Investing.com Australia
Why Jasper Therapeutics stock plunged 60% in one trading session - Dataconomy
Jasper Therapeutics' SWOT analysis: briquilimab's potential reshapes urticaria stock outlook - Investing.com India
Trading (JSPR) With Integrated Risk Controls - Stock Traders Daily
BTIG cuts Jasper Therapeutics price target to $64, maintains Buy By Investing.com - Investing.com Canada
Oppenheimer maintains $80 target on Jasper Therapeutics stock By Investing.com - Investing.com Canada
Jasper’s Briquilimab Stands Up To Competition, But Investors Bail - News & Insights
BTIG cuts Jasper Therapeutics price target to $64, maintains Buy - Investing.com India
Buy rating upheld for Jasper Therapeutics stock as briquilimab progresses in trials - Investing.com Nigeria
Oppenheimer maintains $80 target on Jasper Therapeutics stock - Investing.com India
BMO maintains Jasper Therapeutics Outperform rating - Investing.com
Why Is Jasper Therapeutics Stock Trading Lower On Wednesday?Jasper Therapeutics (NASDAQ:JSPR) - Benzinga
Jasper Therapeutics stock dips following early trial results for chronic hives treatment - Investing.com Canada
Jasper Therapeutics stock tumbles after study data - Investing.com
Jasper Therapeutics Reports Positive Data from BEACON Study of Briquilimab in Chronic Spontaneous Urticaria - GlobeNewswire
Jasper's Briquilimab Achieves 100% Complete Response in Chronic Urticaria Trial Results - StockTitan
Jasper Therapeutics (NASDAQ:JSPR) Earns Market Outperform Rating from JMP Securities - Defense World
Jasper Therapeutics’ SWOT analysis: briquilimab’s potential reshapes urticaria stock outlook - Investing.com Nigeria
Jasper Therapeutics' SWOT analysis: briquilimab stock poised for growth in mast cell disease market - Investing.com Canada
Jasper Therapeutics’ SWOT analysis: briquilimab stock poised for growth in mast cell disease market - Investing.com Nigeria
Jasper Therapeutics (NASDAQ:JSPR) Receives "Market Outperform" Rating from JMP Securities - MarketBeat
Jasper Therapeutics to Host Webinar to Present Preliminary - GlobeNewswire
Jasper Therapeutics to Present Breakthrough CSU Treatment Data in January Webinar - StockTitan
Jasper Therapeutics, Inc. (NASDAQ:JSPR) Stock Position Lifted by Barclays PLC - Defense World
Jasper Therapeutics, Inc. (NASDAQ:JSPR) Holdings Decreased by Geode Capital Management LLC - Defense World
Is Jasper Therapeutics (NASDAQ:JSPR) In A Good Position To Deliver On Growth Plans? - Simply Wall St
Brokerages Set Jasper Therapeutics, Inc. (NASDAQ:JSPR) Price Target at $73.38 - Defense World
Jasper Therapeutics, Inc. (NASDAQ:JSPR) Given Consensus Rating of "Buy" by Analysts - MarketBeat
State Street Corp Raises Stake in Jasper Therapeutics, Inc. (NASDAQ:JSPR) - Defense World
Learn to Evaluate (JSPR) using the Charts - Stock Traders Daily
Jasper Therapeutics (NASDAQ:JSPR) Receives “Outperform” Rating from Royal Bank of Canada - Defense World
Jasper Therapeutics Inc Azioni (JSPR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
4.81%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):